August 31, 2016
…easy and efficient way to coax human pluripotent stem cells to regenerate bone tissue—by feeding them adenosine, a naturally occurring molecule in the body. The stem-cell-derived bone tissue helped repair cranial bone defects in mice without developing tumors or causing infection.
November 26, 2014
…embryos are contemplating their cellular fates in the earliest stages after fertilization when the embryo has only two to four cells, a discovery that could upend the scientific consensus about when embryonic cells begin differentiating into cell types. Their research, which used single-cell RNA sequencing to look at every gene…
August 1, 2013
…reproducible RNA-based method of generating human induced pluripotent stem cells (iPSCs) in the August 1 edition of Cell Stem Cell. Their approach has broad applicability for the successful production of iPSCs for use in human stem cell studies and eventual cell therapies.
September 9, 2021
UC San Diego School of Medicine researchers will receive $6.4 million in National Institutes of Health grant funding to study how external signals and genetic variations influence the behavior of one cell type in particular: insulin-producing beta cells in the pancreas.
June 6, 2017
Researchers at University of California San Diego School of Medicine report that cancer cells appear to communicate to other cancer cells, activating an internal mechanism that boosts resistance to common chemotherapies and promotes tumor survival.
November 24, 2021
The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
February 25, 2015
…first time that the culture conditions in which stem cells are grown and mass-produced can affect their genetic stability.
July 10, 2018
…called PD-L1 to blind T cells from functioning. PD-L1 protects tumors through a “molecular brake” known as PD-1. Researchers have found that some tumor cells display not only their PD-L1 weapon, but also the PD-1 brake, essentially becoming a neutralizing function. The unexpected mechanism could help determine whether a cancer…
August 12, 2021
UC San Diego researchers develop a method to grow hematopoietic stem cells in culture, with clinical implications for bone marrow transplants and aging research.
April 1, 2019
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
